Baseline characteristics of the study cohort who underwent CMR
| All | No new diagnosis group (n = 112) | New diagnosis group (n = 42) | p value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 72 ± 10.0 | 72.6 ± 9.3 | 71.7 ± 11.8 | 0.61 |
| Male | 78 (51) | 54 (48) | 24 (57) | 0.32 |
| Clinical findings | ||||
| Atrial fibrillation | 72 (47) | 50 (45) | 24 (52) | 0.42 |
| Heart rate | 70.4 ± 14.2 | 70.0 ± 13.6 | 71.5 ± 15.8 | 0.57 |
| Systolic Blood Pressure | 143.2 ± 24.9 | 143.6 ± 24.5 | 145.9 ± 25.8 | 0.61 |
| Diastolic Blood Pressure | 74.0 ± 12.2 | 74.0 ± 11.8 | 74.0 ± 13.2 | 0.99 |
| Body Mass Index | 33.9 ± 7.4 | 34.0 ± 6.8 | 33.4 ± 8.7 | 0.66 |
| NYHA | ||||
| I/II | 106 (69) | 77 (69) | 29 (69) | 0.97 |
| III/IV | 48 (31) | 35 (31) | 13 (31) | |
| Medical History | ||||
| Known CAD | 32 (21) | - | - | - |
| Hypertension | 139 (90) | 111 (89) | 39 (93) | 0.60 |
| Diabetes | 75 (49) | 54 (48) | 21 (50) | 0.88 |
| COPD or Asthma | 27 (18) | 17 (15) | 10 (24) | 0.21 |
| Chest radiography | ||||
| Pulmonary oedema | 110 (71) | 79 (71) | 31 (74) | 0.69 |
| Medication | ||||
| Aspirin | 54 (35) | 42 (38) | 12 (29) | 0.30 |
| Beta-blocker | 99 (64) | 74 (66) | 25 (60) | 0.45 |
| ACE inhibitor or ARB | 130 (84) | 97 (87) | 33 (79) | 0.22 |
| Statin | 97 (63) | 70 (63) | 27 (64) | 0.84 |
| Loop diuretic | 125 (81) | 91 (81) | 34 (81) | 0.97 |
| Biochemistry | ||||
| Sodium | 139.2 ± 3.4 | 139.1 ± 3.6 | 139.6 ± 2.6 | 0.39 |
| Urea | 8.7 ± 3.8 | 8.8 ± 4.0 | 8.3 ± 3.5 | 0.46 |
| eGFR | 65.4 ± 18.8 | 66.0 ± 18.7 | 63.5 ± 19.3 | 0.46 |
| BNP (median, IQR) | 144.6 (66 – 259) | 133.6 ± (57.5 – 251.1) | 175.4 ± (110.7 – 262.9) | *0.12 |
| CMR | ||||
| LVEF | 57.0 ± 6.1 | 57.0 ± 5.9 | 57.0 ± 6.5 | 0.98 |
| LVEDVI | 74.3 ± 18.2 | 73.3 ± 16.9 | 77.1 ± 21.4 | 0.26 |
| LVESVI | 32.6 ± 10.6 | 32.1 ± 9.6 | 34.1 ± 12.8 | 0.30 |
ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, BNP: B-type natriuretic peptide, CAD: significant coronary artery disease, CMR: cardiovascular magnetic resonance imaging, COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate, LVEF: left ventricular ejection fraction, LVEDVI left ventricular end-diastolic volume indexed to body surface area, LVESVI: left ventricular end-systolic volume indexed to body surface area.
Values are mean ± SD or n (%). The p values are quoted for the independent-samples T-test or chi-square test for continuous or categorical variables respectively.
* p value refers to zlog10 transformed BNP